Qiaozhi Cao
Hunan Key Laboratory Of Skin Cancer And Psoriasis
Changsha, 410000, China
Changsha, 410000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Microneedle-mediated transdermal delivery of siRNA-loaded nanoparticles for atopic dermatitis therapy by disrupting cuproptosis-pyroptosis crosstalk.
Journal: Journal of nanobiotechnology
Published: February 04, 2026
A Concordance Study between Patient Acceptable Symptom State (PASS) and Disease Activity in Chronic Spontaneous Urticaria.
Journal: Dermatology practical & conceptual
Published: November 06, 2025
Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions.
Journal: Inflammopharmacology
Published: September 18, 2025
The Incidence of Addiction and Its Risk Factors in Chinese Chronic Urticaria Patients.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: February 27, 2025
Atopic Dermatitis and Psoriasis: Similarities and Differences in Metabolism and Microbiome.
Journal: Clinical reviews in allergy & immunology
Published: June 08, 2024
Clinical efficacy of Zhiyang Xiaozhen granules combined with second-generation antihistamine in the treatment of chronic urticaria.
Journal: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Published: May 16, 2024
Predictive features for effectiveness of dupilumab in elderly patients with atopic dermatitis: a real-world study.
Journal: The British journal of dermatology
Published: April 22, 2024
Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis patients with chronic renal insufficiency: a real-world retrospective study in China.
Journal: MedComm
Published: March 19, 2024
PTGS2: A potential immune regulator and therapeutic target for chronic spontaneous urticaria.
Journal: Life sciences
Published: December 01, 2023
Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China.
Journal: Frontiers of medicine
Published: November 13, 2023
Baseline eosinophil level may be a predictive indicator for the effectiveness of dupilumab in patients with prurigo nodularis: A single-center, real-world prospective study.
Journal: Journal of the American Academy of Dermatology
Published: October 01, 2023
Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 19, 2023
Showing 1-12 of 12
Last Updated: 09/26/2026